AGP Executive Report
Last update: 9 hours agoBiotech & Health: Milestone Pharmaceuticals says China’s NMPA has approved etripamil nasal spray for adult PSVT, the first approval outside the US, with Everest Medicines holding a Greater China license covering Macau. Oncology Deal: HUTCHMED and GSK ink a up-to US$1.295bn licensing deal for HMPL-A830, a KRAS-EGFR antibody-targeted therapy conjugate, with development including colorectal, pancreatic and lung cancers. Macao Finance: Macau’s broad money supply (M2) rebounded in July to MOP860.5bn as resident deposits rose and loans to residents declined, according to the Monetary Authority of Macao. Gaming Economy: CBRE flags Macau’s gaming commissions share hitting a new high (20.9% in June quarter) amid a hyper-competitive promo environment, while analysts expect a September GGR rebound after August’s 1.2% year-on-year dip. Low-Altitude Tech: Macau targets 10–15 minute drone deliveries for medical samples between local hospitals, with pilots underway but expansion gated by airspace, customs and standards. Education & Talent: UTM and Universidade Eduardo Mondlane launch a talent development programme at the Macao-Hengqin education town, continuing long-running academic cooperation. Smart Learning in Macau: HIM Business School announces a Master in Applied AI in Customer Experience starting Jan 2027, with in-person immersions in Macao/GBA and Switzerland. ASEAN Links: CE Sam Hou Fai wraps up Indonesia talks, pushing pragmatic Macau–ASEAN cooperation across trade, tourism and healthcare.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
